Isavuconazole and Nine Comparator Antifungal Susceptibility Profiles for Common and Uncommon Candida Species Collected in 2012: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values

Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations

(2013) Barbara D. Alexander et al.   CLINICAL INFECTIOUS DISEASES

Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme

(2013) M.C. Arendrup et al.   CLINICAL MICROBIOLOGY AND INFECTION

In Vitro Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and Molds

(2013) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Impact of First-Line Antifungal Agents on the Outcomes and Costs of Candidemia

(2012) Young Eun Ha et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

ESCMID* *This guideline was presented in part at ECCMID 2011. European Society for Clinical Microbiology and Infectious Diseases. guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)

(2012) A.J. Ullmann et al.   CLINICAL MICROBIOLOGY AND INFECTION

ESCMID* *This guideline was presented in part at ECCMID 2011. European Society for Clinical Microbiology and Infectious Diseases. guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients

(2012) O.A. Cornely et al.   CLINICAL MICROBIOLOGY AND INFECTION

Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study

(2012) J. Auberger et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Assessment of Accuracy of Identification of Pathogenic Yeasts in Microbiology Laboratories in the United Kingdom

(2012) A. M. Borman et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Candida guilliermondii and Other Species of Candida Misidentified as Candida famata: Assessment by Vitek 2, DNA Sequencing Analysis, and Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry in Two Global Antifungal Surveillance Programs

(2012) Mariana Castanheira et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options

(2012) J. C. O. Sardi et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Significance of Molecular Identification and Antifungal Susceptibility of Clinically Significant Yeasts and Moulds in a Global Antifungal Surveillance Programme

(2012) Michael A. Pfaller et al.   MYCOPATHOLOGIA

Antifungal use in hospitalized adults in U.S. academic health centers

(2011) A. L. Pakyz et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing

(2011) Shivaprakash M. Rudramurthy et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Emerging opportunistic yeast infections

(2011) Marisa H Miceli et al.   LANCET INFECTIOUS DISEASES

Emerging moulds: epidemiological trends and antifungal resistance

(2011) Marisa H. Miceli et al.   MYCOSES

In Vitro Antifungal Activities of Isavuconazole and Comparators against Rare Yeast Pathogens

(2010) J. Guinea et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting

(2010) Alexander Lepak et al.   CRITICAL CARE CLINICS

Breakthrough Invasive Candidiasis in Patients on Micafungin

(2010) C. D. Pfeiffer et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Isavuconazole: A Comprehensive Review of Spectrum of Activity of a New Triazole

(2010) George R. Thompson et al.   MYCOPATHOLOGIA

In Vitro Activity of Isavuconazole against Aspergillus Species and Zygomycetes According to the Methodology of the European Committee on Antimicrobial Susceptibility Testing

(2009) S. Perkhofer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America

(2009) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Azole-resistance in Aspergillus: Proposed nomenclature and breakpoints

(2009) Paul E. Verweij et al.   DRUG RESISTANCE UPDATES

New triazoles and echinocandins: mode of action,in vitroactivity and mechanisms of resistance

(2009) Maria Teresa Fera et al.   Expert Review of Anti-Infective Therapy

Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review

(2009) Hsin-Yun Sun et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species

(2009) G. R. Thompson et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In Vitro Activity of the New Azole Isavuconazole (BAL4815) Compared with Six Other Antifungal Agents against 162 Cryptococcus neoformans Isolates from Cuba

(2008) M.-T. Illnait-Zaragozi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Antifungal Activities of Isavuconazole (BAL4815), Voriconazole, and Fluconazole against 1,007 Isolates of Zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium Species

(2008) J. Guinea et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY